## Abstract Currently, Ragaglitazar is being developed as a drug for the treatment of hyperglycaemia and hyperlipidemia in patients with type 2 diabetes. Here, we report the labelling of Ragaglitazar with carbon‐14 and tritium for in vivo and in vitro investigations. Two different carbon‐14 labelle
Synthesis of 13C- and 2H-labelled AZD4619: a selective PPARα agonist
✍ Scribed by Karin Wiklund; Göran N. Nilsson
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- French
- Weight
- 84 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
Conclusions
The synthesis of AZD4619 included 14 steps with an overall yield of 13%. To reach the requirements of an increase in molecular weight by at least nine, both 13 C and 2 H had to be incorporated. According to our previous experiences the loss of deuterium in acidic positions necessitates the use of deuterated solvents and reagents.
📜 SIMILAR VOLUMES
## Abstract The synthesis of the potent dual‐acting PPARα and PPARγ agonist NNC 61‐4655 labelled with tritium and carbon‐14 is reported. Tritium labelled NNC 61‐4655 was obtained in three steps with introduction of tritium through catalytic tritium‐halogen exchange of an aryl bromide precursor. Thi
The incorporation of carbon-13 and deuterium i n the t,2,3-thiadiaxoZe framework i s described.
## Abstract Tryptophan synthase catalyzes the nucleophilic replacement of the hydroxyl group at C‐3 of L‐serine. This enzyme can use benzyl mercaptan as a nucleophile in the conversion of serine to S‐benzyl‐L‐cysteine which is deblocked by treatment with sodium in liquid ammonia to yield L‐cysteine